TWA
STRO icon

TCI Wealth Advisors’s Sutro Biopharma STRO Stock Holding History

TCI Wealth Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$3K – 2515
2021
Q3 		$3K Buy
+17
New +$3.23K ﹤0.01% 2016

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

TCI Wealth Advisors's STRO Position: Q4 2021 in Review

TCI Wealth Advisors sold out of Sutro Biopharma (STRO) in Q4 2021, closing a stake of 17 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in STRO in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2021.

  • TCI Wealth Advisors reported no remaining Sutro Biopharma position as of Q4 2021 after selling out during the quarter.
  • TCI Wealth Advisors sold 17 Sutro Biopharma shares in Q4 2021, an estimated $3K.
  • TCI Wealth Advisors first reported a position in Sutro Biopharma in Q3 2021 and held it in 1 quarter.
  • TCI Wealth Advisors's Sutro Biopharma position peaked at $3K in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.